Verified ComparisonLast updated: 30 March 2026
Tesofensine vs Retatrutide
Tesofensine works via monoamine CNS signaling. Retatrutide is a triple-agonist peptide. Both showed high weight loss in trials; different regulatory trajectories.
Tesofensine
Metabolic
3.8/ 5
B+
Retatrutide
Metabolic
4.8/ 5
A+
Editor's note
Retatrutide is in development with approval potential; Tesofensine development stalled.
| Criterion | Tesofensine | Retatrutide |
|---|---|---|
| Mechanism type | Central nervous system | Peripheral (receptor agonism) |
| Weight loss potential | Very high | Highest reported |
| Development status | Paused (safety concerns) | Phase III ongoing |
| Regulatory approval path | Uncertain | Promising |
| Mechanism clarity | Broad CNS effects | Specific (GLP-1/GIP/GCG) |
Frequently asked questions
Retatrutide; Tesofensine development faced regulatory hurdles.
Want to read the full reviews?